دورية أكاديمية
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
| العنوان: | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. |
|---|---|
| المؤلفون: | Cotes Sanchís, Almudena, Gallego, Javier, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Aguado, Gema, Macias, Ismael, Lopez, Carlos, López, Flora, Visa, Laura, Garrido, Marcelo, Martínez Lago, Nieves, Fernández Montes, Ana, Limón, María Luisa, Azkárate, Aitor, Pimentel, Paola, Reguera, Pablo, Ramchandani, Avinash, Cacho, Juan Diego, Martín Carnicero, Alfonso, Granja, Mónica, Martín Richard, Marta, Hernández Pérez, Carolina, Hurtado, Alicia, Serra, Olbia, Buxo, Elvira, Vidal Tocino, Rosario, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto |
| سنة النشر: | 2020 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Adult, Aged, 80 and over, Antineoplastic Agents, Immunological, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Drug Utilization, Female, Humans, Male, Middle Aged, Platinum Compounds, Registries, Stomach Neoplasms, Survival Analysis |
| الوصف: | Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0.613), lower in those subjects who received second-line (Kendall's τ = 0.539), especially with ramucirumab+CT (Kendall's τ = 0.413). This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1932-6203 |
| العلاقة: | http://hdl.handle.net/10668/16030Test; PMC7394396; https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0235848&type=printableTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394396/pdfTest |
| DOI: | 10.1371/journal.pone.0235848 |
| DOI: | 10.1371/journal.pone.0235848&type=printable |
| الإتاحة: | https://doi.org/10.1371/journal.pone.0235848Test http://hdl.handle.net/10668/16030Test https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0235848&type=printableTest https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394396/pdfTest |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.C229D22D |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0235848 |